Quick Answer
Unicycive Therapeutics, Inc. reported R&D Expense of $9.12 million for fiscal year 2025.
Unicycive Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $9.12M | -54.4% |
| 2024 | $20.01M | +55.1% |
| 2023 | $12.90M | +3.7% |
| 2022 | $12.44M | +104.5% |
| 2021 | $6.08M | +499.0% |
| 2020 | $1.01M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.96M | -2.7% | +69.4% |
| June 30, 2025 | $1.75M | -64.1% | -19.4% |
| March 31, 2025 | $2.17M | -68.1% | -28.7% |
| September 30, 2024 | $3.04M | -9.7% | -37.4% |
| June 30, 2024 | $4.87M | +114.7% | -28.5% |
| March 31, 2024 | $6.81M | +124.9% | +102.0% |
| September 30, 2023 | $3.37M | -29.8% | +48.7% |
| June 30, 2023 | $2.27M | +21.9% | -25.2% |
- Unicycive Therapeutics, Inc. showed a decrease of -54.4% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Unicycive Therapeutics, Inc.’s r&d expense has grown by 798.6% (from $1.01 million to $9.12 million).
- The most recent figure is from Unicycive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: